Psychedelic Medicine

A single psilocybin dose can significantly reduce depression in people with cancer for up to two years, according to a new study. While the study has limitations, it demonstrates the potential of psychedelic therapy in the context of cancer.

A recent study in Denmark looked at whether a single dose of psilocybin could help people reduce their alcohol intake – and the results from the small trial are quite promising. However, they might also warrant greater scrutiny.

A new study has uncovered a previously unknown link between the immune system and the fear response, and how psychedelics can play a role in suppressing it. The finding could improve the treatment of both mental, emotional and physical afflictions.

A new study has found that psilocybin, the psychedelic ingredient in magic mushrooms, could be an effective treatment for repeated mild concussions because of its brain-healing properties. It could be the first medical treatment for the condition.

A landmark clinical trial testing the effect of microdosing LSD on symptoms of ADHD recently delivered its first data readout and the results have been surprising, to say the least, raising questions over the efficacy of this popular trend.

Giving psilocybin to rats made them more optimistic in the longer term, suggesting that the psychedelic substance could have great potential in treating a core symptom of depression in humans.

After comparing the long-term effects of the psychedelic psilocybin and a commonly prescribed antidepressant, new research found that both significantly reduced depression. However, psilocybin provided something more: a significant boost to quality of life.

We were this close to seeing Ecstasy being incorporated into therapy in the US in 2024. Now, we have to wait either a little or a lot – depending on how the chips fall. Let's have a closer look at where we're currently at.

Citizen scientists have been key to the discovery of two new species of hallucinogenic fungi, joining the ranks of 140 known types of these psychoactive mushrooms. One even has longstanding roots in traditional healing medicine in mountainous Lesotho.

Laws are opening up to support the use of medicinal psilocybin – and that requires new technology to ensure accurate, consistent dosing. Researchers have now developed a fast and reliable method of determining the potency of magic mushrooms.

An effective single-dose, long-term treatment for anxiety could be within reach, with the phase 2b clinical trial of MM-120 reported to have passed the stage with flying colors.

A clinical trial has demonstrated that psilocybin-assisted therapy is effective at treating depression in patients with cancer. In a first, the drug was given to small groups of patients simultaneously, before they underwent one-on-one and group therapy.